GeneDx (NASDAQ:WGS) Director Casdin Capital, Llc Purchases 50,000 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc purchased 50,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was purchased at an average price of $52.86 per share, for a total transaction of $2,643,000.00. Following the completion of the purchase, the director owned 3,707,164 shares in the company, valued at approximately $195,960,689.04. The trade was a 1.37% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Casdin Capital, Llc also recently made the following trade(s):

• On Thursday, June 4th, Casdin Capital, Llc purchased 150,000 shares of GeneDx stock. The stock was purchased at an average price of $56.44 per share, for a total transaction of $8,466,000.00.
• On Wednesday, May 20th, Casdin Capital, Llc purchased 140,000 shares of GeneDx stock. The stock was purchased at an average price of $43.81 per share, for a total transaction of $6,133,400.00.
• On Tuesday, May 19th, Casdin Capital, Llc bought 185,000 shares of GeneDx stock. The shares were bought at an average price of $42.60 per share, for a total transaction of $7,881,000.00.
• On Monday, May 18th, Casdin Capital, Llc bought 175,000 shares of GeneDx stock. The shares were bought at an average price of $42.55 per share, for a total transaction of $7,446,250.00.

GeneDx Price Performance

NASDAQ WGS opened at $51.80 on Tuesday. The company has a market capitalization of $1.54 billion, a PE ratio of -19.33 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The business’s fifty day moving average is $55.25 and its 200 day moving average is $92.12. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter last year, the firm posted ($0.23) earnings per share. Sell-side analysts predict that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
• Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
• Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
• Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
• Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article

Analysts Set New Price Targets

WGS has been the topic of several analyst reports. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Jefferies Financial Group set a $150.00 target price on GeneDx in a research report on Monday, February 23rd. Canaccord Genuity Group set a $75.00 target price on GeneDx and gave the company a “buy” rating in a research report on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and set a $130.00 price target (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Finally, Zacks Research cut GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Hedge Funds Weigh In On GeneDx

Several hedge funds have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its position in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the period. Kestra Advisory Services LLC bought a new stake in GeneDx in the fourth quarter worth about $27,000. Fifth Third Bancorp bought a new stake in GeneDx in the first quarter worth about $31,000. Quarry LP lifted its stake in GeneDx by 248.8% in the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after purchasing an additional 209 shares during the last quarter. Finally, Ramirez Asset Management Inc. bought a new stake in GeneDx in the fourth quarter worth about $33,000. 61.72% of the stock is currently owned by institutional investors.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.